Pain Therapeutics Inc. (PTIE)

1.24 +0.08 (+6.897%)

IEX Real-Time Price

March 27, 2019 EST.

NASDAQ Capital Market : Healthcare

Prev Close 1.16

Price Open 1.19

Volume: 294,506

Avg Volume: 224,267

Market Cap: 21.35M

P/E Ratio -1.48

52 Wk Range 0.76-10.8685



PTIE Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
11.46M
2.47M
0.46
21.52%

2018-09-28
11.46M
1.52M
1.88
13.23%

2018-09-14
11.46M
1.65M
0.72
14.41%

2018-08-31
11.46M
1.12M
0.53
9.78%




PTIE Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2019-03-25
Q4 2018
N/A
0.00 (0)
-0.04
0.00

2018-10-29
Q3 2018
AMC
0.00 (0)
-0.11
0.00

2018-07-26
Q2 2018
N/A
0.00 (0)
-0.36
0.00

2018-05-09
Q1 2018
N/A
0.00 (0)
-0.33
0.00

News

Purdue Pharma settles opioid case in OK for $270M (2019-03-26 12:39 SeekingAlpha)

Privately held Purdue Pharma LP has agreed to pay the state of Oklahoma $270M to settle litigation from the AG's office over its role in the opioid crisis there. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, Stocks on…

 


Statistics

Shares Outstanding: 17.22M

Top 15 Institution Percent: 19.10

Price To Sales: N/A

Price To Book: 1.00

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -60.54

Return On Equity: -67.60

Profit Margin: N/A

Price History

Beta: 1.93

50-day Moving Avg: 1.17

200-day Moving Avg: 1.92

YTD Change: 34.42

5-day Change: 1.64

1-month Change: 1.64

3-month Change: 55.00

6-month Change: 25.25

1-year Change: -81.76

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Pain Therapeutics Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.paintrials.com

Pain Therapeutics Inc is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including Remoxy, Oxytrex, PTI-202 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma.